Advancing a recombinant Bacillus Calmette-Guérin (BCG) vaccine through preclinical and clinical studies for the treatment of bladder cancer, the principals of Oncosting LLC are structured around developing novel bladder cancer therapies designed to work in two ways: Harnessing the potency of standard BCG immunotherapy and long-lived delivery of potentSTING agonists using BCG as delivery vehicle, These live BCG-based immunotherapies are engineered to deliver sustained release of potent STING agonists and to retain the known efficacy of traditional BCG against bladder cancer. Propriety technology also reduces adverse events associated with traditional BCG.
